NCT07173751View on ClinicalTrials.gov

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

558

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

September 30, 2030

Conditions
Breast Neoplasms
Interventions
DRUG

Pumitamig

Solution for intravenous (IV) infusion

DRUG

Nab-paclitaxel/Paclitaxel

IV infusion

DRUG

Gemcitabine

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Eribulin

IV infusion

DRUG

Matching placebo

IV infusion

Sponsors

Lead Sponsor

BioNTech SE

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

BioNTech SE

INDUSTRY

NCT07173751 - ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter